88,816 RSUs awarded to 10x Genomics (TXG) director Hindson

Rhea-AI Filing Summary

Hindson Benjamin J. reported acquisition or exercise transactions in this Form 4 filing.

10x Genomics, Inc. reported that director and officer Benjamin J. Hindson received a grant of 88,816 restricted stock units (RSUs) linked to its Class A Common Stock at a stated price of $0.00 per share. Each RSU represents a right to receive one share upon vesting.

According to the award terms, 1/12 of the RSUs will vest on each quarterly anniversary starting on February 21, 2026, as long as Hindson continues as a service provider through each vesting date. After this grant, his directly held Class A Common Stock, including RSUs, totals 513,595 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hindson Benjamin J.

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	88,816	$0.00	--

Holdings After Transaction: Class A Common Stock — 513,595 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hindson Benjamin J.

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/26/2026		A		88,816(1)	A	$0	513,595	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Title: President and Chief Scientific Officer

	/s/ Randy Wu, as Attorney-in-Fact for Benjamin J. Hindson	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Benjamin J. Hindson report in this Form 4 for TXG?

Benjamin J. Hindson reported receiving a grant of 88,816 restricted stock units tied to 10x Genomics Class A Common Stock at a stated price of $0.00 per share. These RSUs convert into shares only as they vest over time.

How many 10x Genomics (TXG) RSUs were granted to Hindson?

Hindson was granted 88,816 restricted stock units. Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting, so the award can convert into 88,816 shares if all vesting conditions are satisfied.

What is the vesting schedule for Hindson’s new TXG RSU grant?

The RSUs vest in 12 equal parts, with 1/12 of the 88,816 units vesting on each quarterly anniversary starting February 21, 2026. Vesting continues only if Hindson remains a service provider on each vesting date.

Does Hindson pay anything for the 10x Genomics RSUs he received?

The filing lists a transaction price of $0.00 per share for the RSU grant, meaning Hindson does not pay cash to receive the units. Value is realized only if and when the RSUs vest into Class A Common Stock.

How many 10x Genomics shares does Hindson hold after this RSU award?

After the RSU grant, Hindson’s total directly held Class A Common Stock, including RSUs, is reported as 513,595 shares. This figure reflects his position following the award reported in this Form 4 filing.

Is this TXG Form 4 a buy or sell transaction for Hindson?

This Form 4 reflects an acquisition through a grant or award, not an open-market buy or sell. The transaction is coded as an award of RSUs, which vest over time rather than being purchased or sold for cash.